Bollag U, Bollag-Albrecht E
Schweiz Med Wochenschr. 1988 Jul 2;118(26):1001-3.
The actual incidence of tuberculosis in Switzerland is below 50 per 100,000 people and if contracted tuberculous disease can be treated readily. These were the main reasons why routine BCG vaccination in neonates was discontinued in 1987. However, the epidemiological and sociodemographic situation may change and it may be necessary to reintroduce BCG vaccination on a large scale. In view of this possibility 70 neonates who had received BCG vaccine after birth were reviewed at the time of MMR vaccination or DT booster vaccination in the second year of life. 34 (44.3%) had a positive response to tuberculin testing (Monotest). Nine had no scar, and more than half of the children with a scar had a negative Monotest. There was no correlation at all between the existence or absence of a BCG scar and a positive or negative tuberculin test. The results support the present immunization policy for tuberculosis in Switzerland, but raise questions on the timing of BCG vaccination at birth.
瑞士结核病的实际发病率低于十万分之五十,并且如果感染了结核病是很容易治疗的。这些是1987年新生儿常规卡介苗接种被停止的主要原因。然而,流行病学和社会人口统计学情况可能会发生变化,可能有必要大规模重新引入卡介苗接种。鉴于这种可能性,对70名出生后接种了卡介苗的新生儿在其1岁时进行麻疹、腮腺炎、风疹联合疫苗(MMR)接种或白喉、破伤风类毒素加强疫苗(DT)接种时进行了复查。34名(44.3%)对结核菌素试验(单克隆菌素试验)呈阳性反应。9名没有疤痕,并且有疤痕的儿童中超过一半结核菌素试验呈阴性。卡介苗疤痕的有无与结核菌素试验的阳性或阴性之间完全没有相关性。这些结果支持瑞士目前的结核病免疫政策,但也对出生时接种卡介苗的时机提出了疑问。